Beton, OsmanAsarcikli, Lale DincSen, TanerIpek, Esra GucukKafes, HabibeYaman, MehmetEfe, Tolga HanKaya, HakkiTemizhan, AhmetYilmaz, Mehmet Birhan2019-07-272019-07-282019-07-272019-07-2820170031-70121423-0313https://dx.doi.org/10.1159/000449389https://hdl.handle.net/20.500.12418/7049Aim: We aimed to evaluate the effect of echocardiographically demonstrated right ventricular dysfunction (RVD) on time in therapeutic range (TTR) in heart failure (HF) patients receiving warfarin therapy. Methods:A total of 893 consecutive HF patients were included and classified into 4 different subgroups: HF with preserved ejection fraction (HFpEF) without RVD (n = 373), HF with reduced EF (HFrEF) without RVD (n = 215), HFpEF with RVD (n = 106) and HFrEF with RVD (n = 199). Groups were compared according to baseline, demographic and clinical data and the characteristics of warfarin therapy. Results: Presence of RVD yielded lower median TTR values both in HFpEF and HFrEF patients. RVD, current smoking, New York Heart Association functional class III/IV, hypertension, diabetes mellitus, pulmonary disease, prior transient ischemic attack or stroke, chronic kidney disease (CKD) stage 4/5 and CKD stage 3 were found to be independent predictors of poor anticoagulation control in multivariate logistic regression analysis. Conclusions: The present study demonstrated that presence of RVD in HF increases the risk for poor anticoagulation. (C) 2016 S. Karger AG, Baselen10.1159/000449389info:eu-repo/semantics/closedAccessWarfarinHeart failureRight ventricular dysfunctionTime in therapeutic rangeArticle9901.Feb2619276544872-s2.0-84988599517Q2WOS:000393268700003Q4